Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SNA02-48 injection for tetanus prophylaxis after high-risk exposure
CTR20262194Phase 3Active
- Sponsor
- Sino Biopharmaceutical Limited
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SNA02-48 in Tetanus, sponsored by Sino Biopharmaceutical Limited. Started Jun 2026; status: active.
02
Drugs
SNA02-48
03
Conditions
Tetanus
Beyond the preview
Go deeper on CTR20262194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262194.